Respiratory syncytial virus (RSV), is responsible for approximately 100,000 deaths and over 3.6 million hospitalizations annually among children under five years old.
The funds will primarily support the clinical development of its lead drug candidate, GE8820, a protein degrader targeting immunoglobulin G4 (IgG4), an antibody subtype implicated in various autoimmune conditions.
Over the next strategic period (2026–2030), low- and middle-income countries are expected to contribute approximately US$4 billion—nearly half of the total costs for vaccination programs supported by Gavi.
The new agreement represents a major step forward in global health cooperation, designed to make the world safer and more equitable when responding to future pandemics.
Launched at the World Heart Summit, the “World Heart Report 2025 – Obesity and Cardiovascular Disease” reveals that many common myths about obesity are making it harder for people to access effective treatment.
Fungal infections such as candida, which leads to oral and vaginal thrush, are increasingly becoming resistant to treatment, raising serious public health concerns.